Victrex (LON:VCT)‘s stock had its “neutral” rating restated by research analysts at UBS Group in a report issued on Monday, ThisIsMoney.Co.Uk reports.
A number of other research firms have also issued reports on VCT. Peel Hunt restated an “add” rating on shares of Victrex in a research report on Monday, May 6th. Numis Securities restated a “hold” rating and set a GBX 2,350 ($30.71) price objective (down previously from GBX 2,550 ($33.32)) on shares of Victrex in a research report on Monday, May 13th. Barclays restated an “underweight” rating and set a GBX 2,210 ($28.88) price objective (down previously from GBX 2,420 ($31.62)) on shares of Victrex in a research report on Friday, March 29th. JPMorgan Chase & Co. reduced their price objective on Victrex from GBX 2,800 ($36.59) to GBX 2,300 ($30.05) and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Finally, Liberum Capital reduced their price objective on Victrex from GBX 2,700 ($35.28) to GBX 2,600 ($33.97) and set a “buy” rating for the company in a research report on Wednesday, May 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 2,367.27 ($30.93).
LON:VCT opened at GBX 2,178 ($28.46) on Monday. Victrex has a 12-month low of GBX 1,943 ($25.39) and a 12-month high of GBX 3,434 ($44.87). The firm has a market cap of $1.88 billion and a price-to-earnings ratio of 18.94. The firm’s 50 day moving average is GBX 2,088.22.
Victrex Company Profile
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Featured Article: What does RSI mean?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.